Evidence-Based Recommendations on the Use of Inclisiran in Patients With Chronic Kidney Disease

Area of Science:

• Cardiology
• Nephrology
• Pharmacology

Background:

• Patients with chronic kidney disease (CKD) face a high risk of atherosclerotic cardiovascular disease (ASCVD).
• Lipid management in CKD is often complicated by polypharmacy, poor adherence, and statin intolerance.
• Inclisiran, a small interfering RNA (siRNA), targets PCSK9 synthesis for effective LDL-cholesterol reduction.

Purpose of the Study:

• To provide evidence-based recommendations for managing dyslipidemia in CKD patients using Inclisiran.
• To introduce a practical stratification tool and treatment algorithm for Inclisiran in CKD.
• To support individualized treatment decisions by comparing Inclisiran with other lipid-lowering agents.

Main Methods:

• Review of available clinical trial evidence on Inclisiran in CKD.
• Consensus-based specialist opinion.
• Development of the Inclisiran Suitability Stratification Tool for CKD.

Main Results:

• Inclisiran presents an innovative, long-acting therapeutic option for lowering LDL-cholesterol in CKD.
• The proposed stratification tool and algorithm aid in selecting appropriate patients and treatment strategies.
• Comparative analysis with other lipid-lowering agents informs clinical decision-making.

Conclusions:

• Inclisiran offers a promising therapeutic avenue for dyslipidemia in the high-risk CKD population.
• The developed tools facilitate the optimal integration of Inclisiran into CKD patient care.
• Individualized treatment approaches are crucial for managing ASCVD risk in CKD.